Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
19 August 2019

Abstract

Anti-cancer therapy with carfilzomib has been associated with cases of cardiac arrest, cardiac failure, and myocardial infarction, including in patients without pre-existing cardiac disorders.